Evidence map›Paper›PMID 32721449›Full record

ReviewEuropean journal of pharmacology2020

OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath.

Ankit Awasthi, Sukriti Vishwas, Leander Corrie, Rajesh Kumar, Rubiya Khursheed, Jaskiran Kaur, Rajan Kumar, K R Arya, Monica Gulati, Bimlesh Kumar and 7 more

Open access · greenAbstract readReview
In one paragraph

Review in European journal of pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 28 citations in OpenAlex.

  1. Machine Learning and COVID-19: Lessons from SARS-CoV-2.Advances in experimental medicine and biology · 2023
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Hydroxyapatite-Coated SPIONs and Their Influence on Cytokine Release.International journal of molecular sciences · 2021
    Article
  8. Science unites a troubled world: Lessons from the pandemic.European journal of pharmacology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Ankit AwasthiSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Sukriti VishwasSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Leander CorrieSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Rajesh KumarSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Rubiya KhursheedSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Jaskiran KaurSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Rajan KumarSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
K R AryaSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Monica GulatiSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Bimlesh KumarSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Sachin Kumar SinghSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India. Electronic address: singhsachin23@gmail.com.
Narendra Kumar PandeySchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Sheetu WadhwaSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Pardeep KumarSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Bhupinder KapoorSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Rajneesh Kumar GuptaSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Ankit KumarSchool of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, 144411, India.
Lovely Professional University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Outbreak of Coronavirus disease 2019 (COVID-19) started in mid of December 2019 and spread very rapidly across the globe within a month of its outbreak. Researchers all across the globe started working to find out its possible treatments. However, most of initiatives taken were based on various hypotheses and till date no successful treatments have been achieved. Some strategies adopted by China where existing antiviral therapy was initially used to treat COVID-19 have not given very successful results. Researchers from Thailand explored the use of combination of anti-influenza drugs such as Oseltamivir, Lopinavir and Ritonavir to treat it. In some cases, combination therapy of antiviral drugs with chloroquine showed better action against COVID-19. Some of the clinical studies showed very good effect of chloroquine and hydroxychloroquine against COVID-19, however, they were not recommended due to serious clinical toxicity. In some cases, use of rho kinase inhibitor, fasudil was found very effective. In some of the countries, antibody-based therapies have proved fairly successful. The use of BCG vaccines came in light; however, they were not found successful due to lack of full-proof mechanistic studies. In Israel as well as in other developed countries, pluristems allogeneic placental expanded cell therapy has been found successful. Some phytochemicals and nutraceuticals have also been explored to treat it. In a recent report, the use of dexamethasone was found very effective in patients suffering from COVID-19. Its effect was most striking among patients on ventilator. The research for vaccines that can prevent the disease is still going on. In light of the dynamic trends, present review focuses on etiopathogenesis, factors associated with spreading of the virus, and possible strategies to treat this deadly infection. In addition, it attempts to compile the recent updates on development of drugs and vaccines for the dreaded disease.

Indexed as

BetacoronavirusCoronavirus InfectionsPandemicsPneumonia, ViralAntiviral AgentsClinical Laboratory TechniquesCommunicable Disease ControlCOVID-19COVID-19 Drug TreatmentCOVID-19 SerotherapyCOVID-19 TestingHumansImmunization, PassiveSARS-CoV-2Treatment OutcomeAntiviral AgentsAntiviral drugsCOVID-19Diagnostic kitsHydroxychloroquinePlasma therapy

Identifiers

PMID32721449
PMCPMC7381902
OpenAlexW3045341679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.